Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer

Lisa Zhang; Myriem Boufraqech; Ross Lake; Electron Kebebew

doi:10.18632/oncotarget.7760

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer

Lisa Zhang, Myriem Boufraqech, Ross Lake and Electron Kebebew _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:16517-16528. https://doi.org/10.18632/oncotarget.7760

Metrics: PDF 2081 views | HTML 3458 views | ?

Abstract

Lisa Zhang1, Myriem Boufraqech1, Ross Lake2 and Electron Kebebew1

1 Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

2 Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, Bethesda, Maryland, USA

Correspondence to:

Electron Kebebew, email:

Keywords: carfilzomib, CUDC-101, anaplastic thyroid cancer, combination therapy, apoptosis

Received: December 16, 2015 Accepted: February 08, 2016 Published: February 26, 2016

Abstract

Anaplastic thyroid cancer (ATC) is one of the most aggressive human malignancies, with no effective treatment currently available. Previously, we identified agents active against ATC cells, both in vitro and in vivo, using quantitative high-throughput screening of 3282 clinically approved drugs and small molecules. Here, we report that combining two of these active agents, carfilzomib, a second-generation proteasome inhibitor, and CUDC-101, a histone deacetylase and multi-kinase inhibitor, results in increased, synergistic activity in ATC cells. The combination of carfilzomib and CUDC-101 synergistically inhibited cellular proliferation and caused cell death in multiple ATC cell lines harboring various driver mutations observed in human ATC tumors. This increased anti-ATC effect was associated with a synergistically enhanced G2/M cell cycle arrest and increased caspase 3/7 activity induced by the drug combination. Mechanistically, treatment with carfilzomib and CUDC-101 increased p21 expression and poly (ADP-ribose) polymerase protein cleavage. Our results suggest that combining carfilzomib and CUDC-101 would offer an effective therapeutic strategy to treat ATC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7760

Publication Alerts

Research Papers:

Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer

Abstract